Immunotherapy · 2019 · 11 citations · 15 references
Life SciencesImmunologyPharmacologyAutoimmunityImmunopharmacologyImmunotherapyAutoimmune DiseasesCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsImmune CheckpointsImmune-related Adverse EventsMyasthenia GravisPd-1 SignalingPd-l1 BlockadeProgrammed Cell Death Ligand 1 InhibitionProgrammed Cell Death Protein 1 (Pd-1) PathwayProgrammed Cell Death Protein 1 InhibitorsProgrammed Death-ligand 1 InhibitionProgrammed Death-ligand 1 InhibitorsSeronegative Myasthenia Gravis
Neurological immune-related adverse events are potentially life-threatening complications of immune checkpoint inhibitors. Myasthenia gravis (MG) is a rare complication of treatment with inhibitors of programmed cell death protein 1 (PD)-1 and PD ligand 1 (PD-L1). We present a patient who developed seronegative MG resulting in respiratory failure while being treated with avelumab for metastatic, treatment-refractory ovarian cancer. Her MG went into remission following steroids and maintenance intravenous immunoglobulin treatment. We conclude that MG is a rare, but potentially life-threatening immune-related adverse event of avelumab therapy. This case provides support to the hypothesis that PD-1/PD-L1 signaling may have a protective role in MG.
15
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Yvette Latchman, Clive R. Wood, Tatyana Chernova et al. · Nature Immunology · 2001 · 2.9K citations
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Hiroyuki Nishimura, Taku Okazaki, Yoshimasa Tanaka et al. · Science · 2001 · 1.9K citations
Life Sciences, Cardiology, Pathology +11